SCHEMBL3016913

SCHEMBL3016913

O=S(=O)(c1cc(C(F)(F)F)ccc1Cl)C1CCN(c2nc(-c3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.52
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CRHBP P24387 1/20 0.44
MC4R P32245 1/20 0.44
CRHR2 Q13324 1/20 0.44
EIF4E P06730 4/20 0.43
ALDH1A1 P00352 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
TSHR P16473 1/20 0.43
ATM Q13315 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.42
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
MAPK1 P28482 1/20 0.41
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018473 0.94 AR (0.45) ARMEN1KMT2ACRHBPMC4R
SCHEMBL3007024 0.93 AR (0.45) ARMEN1KMT2ACRHBPMC4R
SCHEMBL3006719 0.93 SMN1; SMN2 (0.47) ARMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3018558 0.92 AR (0.44) ARMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3009295 0.91 AR (0.43) ARMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3008837 0.91 SMN1; SMN2 (0.49) ARMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3009425 0.91 MEN1 (0.49) ARMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3006658 0.90 SMN1; SMN2 (0.44) ARMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3019368 0.89 SMN1; SMN2 (0.51) ARALDH1A1L3MBTL1SMN1; SMN2RAB9A
SCHEMBL3021903 0.89 AR (0.49) ARMEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.